13
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      New Developments in the Treatment of Pancreatic Cancer: Highlights from the 44th ASCO Annual Virtual Meeting, May 29-31, 2020

      research-article

      Read this article at

      ScienceOpenPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Pancreatic cancer has the worst survival of any solid tumor. Overall, pancreatic cancer accounts for about 3% of all cancers in the US and about 7% of all cancer deaths. The American Cancer Society’s estimates that 57,600 people (30,400 men and 27,200 women) will be diagnosed with pancreatic cancer in the United States for 2020 and approximately 47,050 people (24,640 men and 22,410 women) will die of this disease. FOLFIRINOX, or the combination of gemcitabine with nab-paclitaxel remain to be the major treatment options for these patients for both local and metastatic disease. This slow progress is a result of partly the complex pathogenesis of this disease, and partly the fact that window of opportunity to treat these patients is short as majority of them are diagnosed at an advanced stage. This is a real challenge but also provides an opportunity for new ideas and novel approaches. In this paper, we will present few interesting studies presented at the American Society of Clinical Oncology (ASCO) 2020 virtual Annual Meeting.

          Related collections

          Author and article information

          Journal
          101091810
          26803
          JOP
          JOP
          JOP : Journal of the pancreas
          1590-8577
          15 August 2020
          August 2020
          04 September 2020
          : 21
          : 5
          : 108-111
          Affiliations
          Northwell Health Cancer Institute, Lake Success, NY 11042, USA
          Author notes
          Correspondence Muhammad Wasif Saif, Deputy Physician-in-Chief & Medical Director, Northwell Health Cancer Institute, Professor, Medical Oncology, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, 1111 Marcus Avenue, Lake Success, NY 11042, Tel + (516) 321-2238, Fax + (516) 321-2272, wsaif@ 123456northwell.edu
          Article
          PMC7473328 PMC7473328 7473328 nihpa1619920
          7473328
          32905526
          8b92a9cb-1e0a-494e-bebb-f4a51487e8da
          History
          Categories
          Article

          Treatment Failure,Pancreatic Neoplasms,Oxaliplatin,gemcitabine,Fluorouracil,Carcinoma, Pancreatic Ductal,Adenocarcinoma,RNA,DNA,Genes,Salvage Therapy,Radiotherapy

          Comments

          Comment on this article